✦ LIBER ✦

The return of natalizumab: weighing benefit against risk

✍ Scribed by Douglas Goodin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab for NSCLC: benefits weighed

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Natalizumab update: a story of benefit a

✍ Laurie J. Barten; Douglas R. Allington; Kendra A. Procacci; Michael P. Rivey 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 394 KB

Commentry: Transfusions: weighing the ri

✍ Mark A. Malangoni 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Readministration of abciximab: Weighing

✍ Joel K. Kahn 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 16 KB 👁 1 views

Weighing up the risks and benefits of HR

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

PGI22 WEIGHING TREATMENT BENEFITS AGAINS

✍ FR Johnson; S Özdemir; C Mansfield; BE Sands; CA Siegel; SL Hass; DW Miller; TJ 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB